JP7019727B2 - インフルエンザの治療方法 - Google Patents

インフルエンザの治療方法 Download PDF

Info

Publication number
JP7019727B2
JP7019727B2 JP2019563650A JP2019563650A JP7019727B2 JP 7019727 B2 JP7019727 B2 JP 7019727B2 JP 2019563650 A JP2019563650 A JP 2019563650A JP 2019563650 A JP2019563650 A JP 2019563650A JP 7019727 B2 JP7019727 B2 JP 7019727B2
Authority
JP
Japan
Prior art keywords
influenza
virus
influenza virus
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506243A (ja
JP2020506243A5 (https=
Inventor
エワート，ゲイリー
ラスカム，キャロライン
Original Assignee
バイオトロン リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by バイオトロン リミティッド filed Critical バイオトロン リミティッド
Publication of JP2020506243A publication Critical patent/JP2020506243A/ja
Publication of JP2020506243A5 publication Critical patent/JP2020506243A5/ja
Application granted granted Critical
Publication of JP7019727B2 publication Critical patent/JP7019727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019563650A 2017-02-08 2018-02-07 インフルエンザの治療方法 Active JP7019727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900385 2017-02-08
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (3)

Publication Number Publication Date
JP2020506243A JP2020506243A (ja) 2020-02-27
JP2020506243A5 JP2020506243A5 (https=) 2021-03-11
JP7019727B2 true JP7019727B2 (ja) 2022-02-15

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563650A Active JP7019727B2 (ja) 2017-02-08 2018-02-07 インフルエンザの治療方法

Country Status (12)

Country Link
US (1) US10918623B2 (https=)
EP (1) EP3579833B1 (https=)
JP (1) JP7019727B2 (https=)
KR (1) KR102607599B1 (https=)
CN (1) CN110325187B (https=)
AU (1) AU2018218179B2 (https=)
BR (1) BR112019016316A2 (https=)
ES (1) ES2910136T3 (https=)
MX (1) MX387115B (https=)
RU (1) RU2769317C2 (https=)
SG (1) SG11201907034PA (https=)
WO (1) WO2018145148A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
EP4346772B1 (en) 2021-05-26 2026-04-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN118574614A (zh) * 2021-11-24 2024-08-30 生物环境有限公司 治疗sars-cov-2感染的方法
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
PE20250419A1 (es) 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
JP2025519390A (ja) 2022-06-06 2025-06-26 ギリアード サイエンシーズ， インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL326322A (en) 2023-08-31 2026-04-01 Gilead Sciences Inc Antiviral compounds and methods for their production and use
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543886A (ja) 2005-06-24 2008-12-04 バイオトロン リミテッド 抗ウイルス化合物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543886A (ja) 2005-06-24 2008-12-04 バイオトロン リミテッド 抗ウイルス化合物および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. D. Balgi et al.，Inhibitors of the Influenza A Virus M2 Proton Channel Discovered Using a High-Throughput Yeast Growth Restoration Assay，PLOS One，2013年02月01日，8 (2)，e55271
J. L. Nieva et al.，Viroporins: structure and biological functions，Nature Reviews Microbiology，2012年08月，10，563-574
J. Wilkinson et al.，A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection，J. of Antimicrobial Chemotherapy，2016年，71，731-738
P. H. Jalily et al.，Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride，Molecular Pharmacology，2016年08月，90 (2)，80-95

Also Published As

Publication number Publication date
EP3579833A4 (en) 2021-01-13
BR112019016316A2 (pt) 2020-03-31
MX2019009443A (es) 2019-12-16
JP2020506243A (ja) 2020-02-27
CA3052503A1 (en) 2018-08-16
RU2019126746A (ru) 2021-03-09
SG11201907034PA (en) 2019-08-27
RU2769317C2 (ru) 2022-03-30
US10918623B2 (en) 2021-02-16
CN110325187A (zh) 2019-10-11
KR20190112051A (ko) 2019-10-02
US20200093796A1 (en) 2020-03-26
AU2018218179A1 (en) 2019-08-22
ES2910136T3 (es) 2022-05-11
EP3579833A1 (en) 2019-12-18
AU2018218179B2 (en) 2023-05-04
KR102607599B1 (ko) 2023-11-28
CN110325187B (zh) 2022-09-30
WO2018145148A1 (en) 2018-08-16
RU2019126746A3 (https=) 2021-05-28
NZ755900A (en) 2025-03-28
MX387115B (es) 2025-03-19
EP3579833B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
JP7019727B2 (ja) インフルエンザの治療方法
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
US11433080B2 (en) Antiviral treatment
US10221152B2 (en) Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
US20230225988A1 (en) Antiviral use of calixarenes
CN118574614A (zh) 治疗sars-cov-2感染的方法
CA3052503C (en) Methods of treating influenza
CN110870864A (zh) 马来酸卡比沙明在制备抗流感病毒药物中的应用
HK40017310B (en) Methods of treating influenza
HK40017310A (en) Methods of treating influenza
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
WO2019089734A1 (en) Methods and compositions for the treatment of influenza
TWI530284B (zh) 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途
CN115414370A (zh) 牛磺胆酸钠在制备治疗或预防流感病毒感染的药物中的应用
HK40087524A (zh) 氮卓斯汀用作抗病毒治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220202

R150 Certificate of patent or registration of utility model

Ref document number: 7019727

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250